Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
2021
Recent studies reported negative predictors for immune checkpoint inhibitors (ICI) in non–small cell lung cancer (NSCLC), including STK11, KEAP1 , and PTEN ([1–3][1]). Aggarwal and colleagues' study showed that patients with NSCLC with high blood-based tumor mutation burden (bTMB) and absence of
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
0
Citations
NaN
KQI